Drug Price Blueprint: The Likely Impact
American Patients First, the Trump Administration’s “blueprint to lower drug prices,” contains provisions with the potential for a significant impact on the health care marketplace, according to Alex Jung, managing director in the Parthenon-EY practice of Ernst & Young LLP.